Health Trials

Seizures, Focal

3

Review clinical trials related to Seizures, Focal. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

The purpose of this research is to determine the optimal dose, safety and tolerability of zonisamide oral suspension in children ages 1 month to 17 years of age who have partial-onset (focal) seizures. The study consists of four periods: a Screening Period (about 14 days), a Titration Period (8 weeks), a Maintenance Period (4 weeks), and a Follow-Up Period (1 week).

Participants needed: 40
Trial details
Phase: Phase 4Age: 1-17Biological sex: AllType: InterventionalSponsor: Azurity PharmaceuticalsUpdated: Jun 4, 2026Locations: 2
Eligibility criteria

Voluntarily obtained informed consent from parent/legal guardian of the particip... [+15]

Known hypersensitivity to zonisamide or to any component of the investigational... [+15]

Read more
Status: Recruiting

A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

This will be a prospective, pilot, open-label, two-arm, parallel-group, randomized study to evaluate the efficacy and safety of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant epilepsy (DRE).

Participants needed: 16
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: NaviFUS CorporationUpdated: Apr 9, 2026Locations: 1
Eligibility criteria

Male or female patients aged over than and equal to 18 years old. [+4]

Patients with concurrent active psychiatric or mood disorders that have been ass... [+19]

Read more
Status: Recruiting

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant unilateral or bilateral temporal lobe epilepsy (DR-TLE).

Participants needed: 8
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: NaviFUS CorporationUpdated: Apr 9, 2026Locations: 3
Eligibility criteria

Male or female patients ≥ 18 years of age at the time of enrollment. [+10]

Patients who have primary generalized epilepsy, mixed focal and generalized epil... [+14]

Read more